Aster DM Multispecialty Hospital Private Limited (ADMPL), a subsidiary of aster dm healthcare , has allotted 39,80,000 Compulsorily Convertible Preference Shares (CCPS) to identified investors on a preferential basis by way of private placement. The allotment was approved by ADMPL's board on June 16, 2026, pursuant to Regulation 30(7) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The issuance comprises both fully paid-up and partly paid-up shares, with a conversion ratio of up to 5 equity shares of ADMPL for each CCPS.

Breakdown of Allotment

The board allotted two distinct series of CCPS. Series A shares are fully paid-up, while Series B shares are partly paid-up. Both series carry a face value of Rs. 50 each.

Conversion and Shareholding Structure

The CCPS issued will convert into equity shares of ADMPL. As on the date of allotment, the conversion ratio stipulates that each CCPS shall convert into a maximum of up to 5 equity shares of ADMPL. This conversion mechanism will dilute the shareholding of existing stakeholders, subject to the terms approved by ADMPL shareholders.

Aster DM Healthcare disclosed that its shareholding in ADMPL will not go below 75% of the share capital on an as-if converted basis. This threshold accounts for the conversion of the allotted Series A CCPS, Series B CCPS, and any Additional Investment that ADMPL may finalize in the future.

Future Capital Raising Plans

ADMPL is actively pursuing further capital infusion. The subsidiary is in the process of finalizing other investors to whom certain other CCPS may be issued in due course. This prospective issuance is referred to as Additional Investment. The company confirmed that the 75% minimum shareholding commitment for Aster DM Healthcare remains valid even after this Additional Investment is accounted for.

The filing was submitted by Hemish Purushottam, Company Secretary and Compliance Officer of Aster DM Healthcare Limited.

Aster DM Healthcare Limited has initiated the process to secure central government approval for the appointment of Dr. Mandayapurath Azad Moopen as Executive Director. The company published a notice to members on June 5, 2026, pursuant to Section 201 of the Companies Act, 2013, outlining its intention to apply for the necessary sanctions. This regulatory step is required to formalize the directorship and associated remuneration for the specified period.

The appointment, which covers the period from April 15, 2026 to May 28, 2026, was previously approved by the Board of Directors on March 10, 2026. Shareholders subsequently endorsed the proposal through a postal ballot conducted via electronic voting on April 12, 2026. The company is now moving to satisfy the final regulatory requirements under Sections 196, 197, and 201 of the Companies Act, read with Schedule V.

Key Details of the Appointment

The notice specifies that the application to the Central Government encompasses both the appointment of Dr. Moopen and the payment of his remuneration. The terms and conditions governing this role were established by the Board and ratified by the shareholders earlier this year.

The publication of this notice in newspapers such as the Financial Express and AndhraJyothy serves as a formal intimation to the members regarding the company's compliance with the statutory provisions. The company has also made the information available on its official website.